MEK inhibitors in non-V600 BRAF mutations and fusions

Douglas B. Johnson; Caroline A. Nebhan; Marcus S. Noel

doi:10.18632/oncotarget.27788

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

MEK inhibitors in non-V600 BRAF mutations and fusions

Douglas B. Johnson _, Caroline A. Nebhan and Marcus S. Noel

PDF | Full Text | How to cite

Oncotarget. 2020; 11:3900-3903. https://doi.org/10.18632/oncotarget.27788

Metrics: PDF 1918 views | Full Text 2990 views | ?

Abstract

Douglas B. Johnson1, Caroline A. Nebhan1 and Marcus S. Noel2

1 Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA

2 Department of Medicine, Georgetown University Medical Center, Washington, DC, USA

Correspondence to:

Douglas B. Johnson,

email:

[email protected]

Keywords: trametinib; MEK; BRAF; atypical; fusion

Received: October 09, 2020 Accepted: October 13, 2020 Published: November 03, 2020

Copyright: © 2020 Johnson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with MEK inhibitors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27788

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Perspectives:

MEK inhibitors in non-V600 BRAF mutations and fusions

Abstract